Allurion Technologies Inc Revenue Growth Rates (ALUR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Allurion Technologies Inc   (ALUR)
 

ALUR's Revenue Growth by Quarter and Year

Allurion Technologies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALUR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 2.95
FY 2.95





ALUR Revenue first quarter 2026 Y/Y Growth Comment
Allurion Technologies Inc reported fall in Revenue in the first quarter 2026 by -42.89% to $ 2.95 millions, from the same quarter in 2025.
Despite modest results in the first quarter 2026, contraction in Allurion Technologies Inc 's Revenue appears to be smaller than Company's recent average decline.

Looking into first quarter 2026 results within Medical Equipment & Supplies industry 150 other companies have achieved higher Revenue growth. While Allurion Technologies Inc ' s Revenue drop of -42.89% ranks overall at the positon no. 3686 in the first quarter 2026.


ALUR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -42.88 % -20.75 % -74.17 %
3rd Quarter September - -54.99 % -71.56 % 11.89 %
2nd Quarter June - -69.24 % -8.19 % -26.34 %
1st Quarter March -42.89 % -41.83 % -36.96 % -
FY   - -53.75 % -39.71 % -

Financial Statements
Allurion Technologies Inc 's first quarter 2026 Revenue $ 2.95 millions ALUR's Income Statement
Allurion Technologies Inc 's first quarter 2025 Revenue $ 5.16 millions Quarterly ALUR's Income Statement


ALUR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 62.17 % 27.79 % -54.15 %
3rd Quarter September - -31.95 % -53.5 % 50.13 %
2nd Quarter June - -34.5 % 23.9 % -14.93 %
1st Quarter March -20.99 % -20.98 % 7.65 % -55.89 %
FY (Year on Year)   - -53.75 % -39.71 % -


Back to ALUR Growth rate Comparisons >> Back to ALUR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #151
Healthcare Sector #476
Overall #3686

Revenue Y/Y Growth Statistics
High Average Low
-53.75 % -59.48 % -66.43 %
(Dec 31 2025)   (Jun 30 2025)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #151
Healthcare Sector #476
Overall #3686
Revenue Y/Y Growth Statistics
High Average Low
-53.75 % -59.48 % -66.43 %
(Dec 31 2025)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Allurion Technologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
98.56 % -0.51 % -60.25 %
(Dec 31 2022)  


ALUR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Allurion Technologies Inc disclosed fall in Revenue from the fourth quarter by -20.99% to $ 2.95 millions, from $ 3.73 millions achived in the previous reporting period.

But that's not important problem, as Allurion Technologies Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 166 other companies have achieved higher Revenue quarter on quarter growth. While Allurion Technologies Inc 's Revenue growth quarter on quarter, overall rank is 3406.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #167
Healthcare Sector #506
Overall #3406
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #167
Healthcare Sector #506
Overall #3406
Revenue Q/Q Growth Statistics
High Average Low
98.56 % -0.51 % -60.25 %
(Dec 31 2022)  


ALUR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Allurion Technologies Inc disclosed fall in Revenue from the fourth quarter by -20.99% to $ 2.95 millions, from $ 3.73 millions achived in the previous reporting period.

But that's not important problem, as Allurion Technologies Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 166 other companies have achieved higher Revenue quarter on quarter growth. While Allurion Technologies Inc 's Revenue growth quarter on quarter, overall rank is 3406.


Allurion Technologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 12.36 $ 14.57 $ 17.38 $ 20.18 $ 27.80
Y / Y Revenue Growth (TTM) -55.55 % -53.75 % -47.67 % -56.18 % -40.9 %
Year on Year Revenue Growth Overall Ranking # 3811 # 3010 # 3271 # 2868 # 0
Seqeuential Revenue Change (TTM) -15.19 % -16.15 % -13.91 % -27.39 % -11.76 %
Seq. Revenue Growth (TTM) Overall Ranking # 3686 # 3131 # 2782 # 1987 # 0


Cumulative Revenue growth Comment
Allurion Technologies Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -55.55% year on year, at Mar 31 2026 compare to the -53.75% decrease at Dec 31 2025. If the Allurion Technologies Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $12 millions.

In the Healthcare sector 509 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3010 to 3811.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 151
Healthcare Sector # 510
Overall # 3811

Revenue TTM Y/Y Growth Statistics
High Average Low
-53.75 %
 -59.48 %
-66.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 476
S&P 500 # 3686
Cumulative Revenue growth Comment
Allurion Technologies Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -55.55% year on year, at Mar 31 2026 compare to the -53.75% decrease at Dec 31 2025. If the Allurion Technologies Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $12 millions.

In the Healthcare sector 509 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3010 to 3811.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 151
Healthcare Sector # 510
Overall # 3811

Revenue TTM Y/Y Growth Statistics
High Average Low
-53.75 %
-59.48 %
-66.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 476
S&P 500 # 3686




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALUR's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Allurion Technologies Inc Revenue Growth Rates (ALUR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Allurion Technologies Inc (CIK 1964979).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-226960
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Allurion Technologies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.